STOCK TITAN

Kezar Life Sciences - KZR STOCK NEWS

Welcome to our dedicated page for Kezar Life Sciences news (Ticker: KZR), a resource for investors and traders seeking the latest updates and insights on Kezar Life Sciences stock.

Kezar Life Sciences (KZR) is a clinical-stage biotechnology company pioneering novel small molecule therapeutics for autoimmune disorders and oncology. This page provides authoritative updates on corporate developments, clinical research, and strategic initiatives essential for informed decision-making.

Access real-time updates on KZR-616 clinical trials, regulatory milestones, and scientific advancements alongside financial disclosures and partnership announcements. Our curated news collection serves investors, researchers, and healthcare professionals seeking comprehensive insights into the company’s progress.

Key coverage areas include immunoproteasome inhibitor developments, trial phase updates, intellectual property news, and collaborative research efforts. All content undergoes rigorous verification to ensure alignment with SEC filings and peer-reviewed publications.

Bookmark this page for streamlined access to KZR’s latest material events. Combine our news monitoring with SEC filings and medical journals for complete due diligence.

Rhea-AI Summary

Kezar Life Sciences (Nasdaq: KZR) announced that Co-founder and Chief Scientific Officer, Christopher Kirk, will join the panel discussion on "Novel Targets for Autoimmune Diseases" at William Blair's Biotech Focus Conference on July 15, 2021, at 11:00 a.m. ET. The event will be webcast live, accessible through the Events & Presentations section of Kezar's website, with a replay available for 90 days post-conference. Kezar focuses on innovative treatments for autoimmune diseases and cancer, including KZR-616, currently in Phase 2 trials for lupus nephritis and other conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.22%
Tags
conferences
-
Rhea-AI Summary

Kezar Life Sciences (Nasdaq: KZR) has established a Clinical Advisory Committee to enhance clinical development strategies for its lead candidate, KZR-616, aimed at autoimmune diseases. This committee, comprising experts from various medical fields, will guide the company's therapeutic programs and patient-centric approaches. KZR-616 is a first-in-class selective immunoproteasome inhibitor currently undergoing Phase 2 trials for severe autoimmune conditions, demonstrating a favorable safety profile in earlier studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
none
-
Rhea-AI Summary

Kezar Life Sciences, Inc. (Nasdaq: KZR) announced results from the Phase 1b dose escalation of its MISSION study, focusing on KZR-616 for systemic lupus erythematosus (SLE). This first-in-class immunoproteasome inhibitor showed favorable safety and tolerability in 47 patients. The study observed significant improvement in disease activity scores, including reductions in anti-double-stranded DNA antibodies. Among patients with proliferative lupus nephritis, notable reductions in urine protein levels were recorded. The poster presented at EULAR highlights KZR-616's potential to transform treatment for SLE and lupus nephritis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.69%
Tags
Rhea-AI Summary

Kezar Life Sciences, Inc. (Nasdaq: KZR) has appointed Dr. Micki Klearman to its Board of Directors. Dr. Klearman, who brings over a decade of biopharmaceutical expertise, has significantly advanced treatments for autoimmune diseases such as rheumatoid arthritis and Giant Cell Arteritis during her tenure at Genentech/Roche. Her addition is expected to enhance Kezar's strategic direction as the company focuses on developing innovative therapies for immune-mediated diseases. This leadership change aims to leverage Dr. Klearman's experience to drive the company's research and clinical programs forward.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.69%
Tags
management
-
Rhea-AI Summary

Kezar Life Sciences, a clinical-stage biotechnology firm focusing on immune-mediated and oncologic disorders, announced that CEO John Fowler will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 2:00 p.m. ET. The chat will be accessible via live webcast on the company's website, with a replay available for 90 days post-event. Kezar is developing innovative therapies, including KZR-616 for lupus nephritis and KZR-261, targeting cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
conferences
-
Rhea-AI Summary

Kezar Life Sciences (Nasdaq: KZR) will present a MISSION Phase 1b data update on June 2, 2021, at 4:30 p.m. ET during EULAR 2021. This event will showcase final data from a 25-week study assessing the safety and tolerability of KZR-616 in 47 patients with systemic lupus erythematosus. KZR-616, a first-in-class selective immunoproteasome inhibitor, has shown a favorable safety profile in earlier trials and is being evaluated for severe autoimmune diseases, with ongoing Phase 2 trials in lupus nephritis and other conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
conferences clinical trial
Rhea-AI Summary

Kezar Life Sciences (Nasdaq: KZR) announced its Q1 2021 financial results, reporting a net loss of $13 million, or $0.25 per share. Cash, cash equivalents, and marketable securities totaled $142.3 million. R&D expenses increased to $9.3 million, driven by the KZR-616 program. The company is advancing two clinical trials: MISSION for SLE and lupus nephritis, and PRESIDIO for dermatomyositis and polymyositis. KZR-261, a new protein secretion inhibitor, is on track for an IND submission by mid-2021. Interim data is expected later this year, showcasing ongoing development and commitment to growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.46%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.26%
Tags
none
-
Rhea-AI Summary

Kezar Life Sciences presented preclinical data on its protein secretion program at the AACR 2021 Virtual Annual Meeting. The analysis focused on KZR-261, a small molecule inhibitor targeting the Sec61 translocon, which may offer novel therapies for various tumor indications. Preliminary findings suggest that KZR-261 shows sensitivity in certain tumor types while sparing normal cells. An IND application is expected by mid-2021, paving the way for a Phase 1 trial assessing its safety and anti-tumor activity in solid tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Kezar Life Sciences, Inc. (KZR) reported its financial results for Q4 and full year 2020, highlighting advances in its clinical programs despite challenges. The company’s lead candidate, KZR-616, is progressing in multiple trials, with FDA orphan drug designations granted for specific conditions. Financially, cash and equivalents rose to $140.4 million, while R&D expenses increased due to ongoing clinical trials, leading to a Q4 net loss of $10.9 million. Looking ahead, the company anticipates interim data from its key studies in 2021, supporting its strategic development goals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.66%
Tags
Kezar Life Sciences

Nasdaq:KZR

KZR Rankings

KZR Stock Data

30.32M
6.23M
12%
62%
0.64%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO